DataMeds AI Announces LOI for Acquisition, Major Equity Issuance

What Happened

• DataMeds AI, Inc. (MEDS) filed an 8-K on August 4, 2026 disclosing an Amended and Restated Letter of Intent (LOI) dated July 29, 2026 with EOS Technology Holdings, Inc., Scilex Holding Company, Datavault AI Inc., and HealthBridge Advisors, LLC (Fortitude Advisors is referenced but not a LOI party).
• Under the LOI, subject to definitive agreements and closing conditions, the company would (a) acquire or exclusively license certain Quality of Life / Peace of Mind (QOLPOM / QLPM) intellectual property from EOS and Scilex, (b) expand its existing PharmacyChain license with Datavault to include Datavault AI Health (with specified carve-outs), and (c) acquire a controlling interest in Tollo Health, LLC via an exchange with HBA. The LOI replaces a prior May 18, 2026 term sheet.

Key Details

• LOI date: July 29, 2026; 8-K filed: August 4, 2026.
• Proposed consideration: issuance of common stock ("Acquisition Stock") only (no preferred or convertible securities); target post-closing ownership on a fully diluted basis: EOS 19.9%, Scilex 19.9%, Datavault 19.9%, HBA 24.9% (aggregate ~84.6%); Fortitude ~5%; existing public shareholders ~10.4% (subject to a capitalization model and adjustments).
• The LOI contemplates liability reduction and financing steps before closing; unsettled liabilities may reduce Acquisition Stock issuable to HBA under a liability reduction framework.
• Corporate governance changes expected at closing: two new management hires mutually agreed by parties and four board designees (one each for EOS, Scilex, Datavault, HBA); transfer restrictions (including a six-month lock-up for certain holders) and registration rights (file Form S-3 or S-1 within 45 days; use efforts to be effective within 90 days).
• Transaction remains subject to due diligence, negotiation of definitive agreements, a fairness opinion, board and stockholder approvals, financing availability, and Nasdaq requirements (possible change-of-control impacts).

Why It Matters

• If completed as described, the deal would substantially shift ownership and control—new parties would collectively target roughly 84.6% of the company on a fully diluted basis—diluting current public shareholders to about 10.4% (subject to adjustments).
• The transaction would reposition DataMeds AI’s business via new IP and a controlling interest in Tollo, plus management and board changes that could change strategy and operations.
• Important caveats: the LOI is a non‑binding framework for many terms, the transaction requires multiple approvals and financing, and there is no assurance definitive agreements will be executed or the deal will close.